Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR) announced that its biomarker studies on Friedreich's ataxia will be presented at the Gordon Research Conference on Mitochondria and Chloroplasts from July 17-22, 2022. The study highlights differentially expressed genes between healthy individuals and those with Friedreich's ataxia, focusing on potential treatment pathways. The oral presentation will occur on July 21, 2022, at 8:40 PM ET by David Bettoun, Ph.D., the company's Vice President of Discovery and Non-clinical R&D.

Positive

• Presentation at a prominent conference highlights significant research on Friedreich's ataxia.
• Focus on developing targeted treatments aligns with the company's mission in rare diseases.

Negative

• None.

BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts during the session on “Organelle Biology Translated into Medicine and Agriculture.” The conference will take place July 17 – 22, 2022 at Mount Snow in West Dover, Vermont.

Details on the presentation are shown below.

Presentation Title:	Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients
Presenting Author:	David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics
Presentation Date:	July 21, 2022
Presentation Time:	8:40 PM ET

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is the focus of Larimar Therapeutics' presentation at the Gordon Research Conference?

The presentation focuses on identifying differentially expressed genes in Friedreich's ataxia patients.

When is Larimar Therapeutics' presentation scheduled?

The presentation is scheduled for July 21, 2022, at 8:40 PM ET.

Where is the Gordon Research Conference being held?

The conference is being held at Mount Snow in West Dover, Vermont.

Who is presenting the research at the conference?

David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, will present the research.

What is Larimar Therapeutics developing for Friedreich's ataxia?

Larimar is developing a lead compound, CTI-1601, as a potential treatment for Friedreich's ataxia.